RK

Ravi Kambhampati Kumar

Active Director Director DIN 06967094
DIN 06967094 First appointment Sep 2014 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2014
Shareholding value β€’β€’β€’β€’ Premium profile

About Ravi Kambhampati Kumar

Data last updated:

Ravi Kambhampati Kumar is a Director at Vivit Pharma India Private Limited (since 2014). The company operates in Chemicals.

DIN 06967094
Primary Designation Director
Industry Chemicals
First Appointment 29 Sep 2014
Oldest Company Age 12 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Vivit Pharma India Private Limited U24240TG2014PTC095864
Director29 Sep 20142014Under Process Of Striking Off

Board colleagues of Ravi Kambhampati Kumar

NameDINCompanyDesignation
Kambhampati Vani Kumari06510965Vivit Pharma India Private LimitedDirector

Directorship timeline

Open interactive timeline →
Vivit Pharma India Private Limited
Premium access

Shareholding and investment profile for Ravi Kambhampati Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravi Kambhampati Kumar

Ravi Kambhampati Kumar currently holds 1 directorship: Vivit Pharma India Private Limited (Director, since 29 Sep 2014).

Ravi Kambhampati Kumar was first appointed on 29 Sep 2014 as Director at Vivit Pharma India Private Limited.

The current boards of Ravi Kambhampati Kumar's companies include Kambhampati Vani Kumari (Vivit Pharma India Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available